News

Antibiotic dalbavancin (Dalvance), previously approved to treat bacterial skin infections in adults, received FDA approval for the pediatric population from birth, manufacturer AbbVie said in a press release on Friday. Dalbavancin was described as the first single-dose option given as a 30-minute intravenous infusion to treat acute bacterial skin and skin structure infections (ABSSSIs) caused
0 Comments
The American Hospital Association (AHA) — which represents nearly 5,000 hospitals and healthcare systems in the U.S. — publicly affirmed its support for COVID-19 vaccine mandates for healthcare workers in a statement released on Wednesday. The announcement comes only a few days after a federal judge decided that Indiana University’s vaccine requirements will remain in
0 Comments
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The drugmaker Pfizer recently announced that vaccinated people are likely to need a booster shot to be effectively protected against new variants of covid-19 and that the company would apply for Food and Drug Administration emergency use authorization for the shot.
0 Comments
Sickle cell disease (SCD) was associated with a significantly increased risk of COVID-19-related hospitalization and death in adults, U.K. researchers found. Their cohort study showed that having SCD quadrupled a person’s risk for COVID-19-related hospitalization (HR 4.11, 95% CI 2.98-5.66), and more than doubled the risk of death (HR 2.55, 95% CI 1.36-4.75), reported Ashley
0 Comments
After an incredible start, the UK’s vaccination programme is now slowing down. Over 80 million doses have been administered, but more than 10% of the UK adult population still hasn’t been vaccinated. With COVID-19 cases once again rising, the question of how to boost vaccine uptake among the hesitant is a pressing concern. Previous research
0 Comments
A small study conducted in rhesus macaques found a 10-fold reduction in HIV viral load when the monkeys received immunotherapy to block programmed cell death protein–1 (PD-1) and the cytokine interleukin-10 (IL-10). Additionally, 8 of 10 monkeys in the study experienced HIV-like simian immunodeficiency virus (SIV) levels of <1000 copies for up to 12 weeks.
0 Comments
While wireless earbuds make taking calls, watching videos and listening to music on the go more convenient, can these earbuds be bad for your hearing? Here’s what you need to know.  The Rise of Wireless Earbuds Since its launch, Apple has sold 100+ million AirPods, making it the most popular wireless earbuds globally. In the years that
0 Comments
The FDA approved intravenous immunoglobulins (IVIG; Octagam 10%) for treating adults with dermatomyositis, a rare chronic autoimmune disease, drugmaker Octapharma announced on Tuesday. Support for the indication was based on findings from ProDERM, a phase III placebo-controlled trial of 95 adults with dermatomyositis. Responses with IVIG treatment (2 g/kg) every 4 weeks more than doubled
0 Comments
While the COVID-19 vaccines currently available in the U.S. have been proved to be safe and effective, recent reports of rare adverse events, or side effects, have raised concerns. On July 12, 2021, the Food and Drug Administration approved an update to the Johnson & Johnson COVID-19 vaccine fact sheet to include an increased risk
0 Comments
Headache was the most common adverse event (AE) people experienced in 72 weeks of taking the once-daily investigational two-drug HIV treatment islatravir (ISL; Merck) plus doravirine (DOR; Merck), and those AEs were short-lived and mild, according to a safety analysis presented at the International AIDS Society (IAS) Conference 2021. That finding, combined with other data
0 Comments
Palomar Health, a public healthcare district with two hospitals in North San Diego County, is under fire — from both its own staff and North County residents — after its board privately negotiated new contracts with two physician staffing companies. A spokesperson for Palomar Health confirmed that their CEO, Diane Hansen, signed three contracts with
0 Comments